A de-risking approach was developed to evaluate the robustness of the Staudinger aza-Wittig sequence. This technology is based on [¹⁴C]CO₂ screening that allowed to investigate the tolerance of the procedure with most representative heterocycles and functional groups found in FDA drugs.

中文翻译：

---

使用 14C 标记的二氧化碳进行平行筛选：降低施陶丁格-氮杂-维蒂希反应的风险**

开发了一种去风险方法来评估 Staudinger aza-Wittig 序列的稳健性。该技术基于 [ ¹⁴ C]CO ₂筛选，允许调查该程序对 FDA 药物中发现的最具代表性的杂环和官能团的耐受性。